RU2017126025A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2017126025A3 RU2017126025A3 RU2017126025A RU2017126025A RU2017126025A3 RU 2017126025 A3 RU2017126025 A3 RU 2017126025A3 RU 2017126025 A RU2017126025 A RU 2017126025A RU 2017126025 A RU2017126025 A RU 2017126025A RU 2017126025 A3 RU2017126025 A3 RU 2017126025A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462095361P | 2014-12-22 | 2014-12-22 | |
| US62/095,361 | 2014-12-22 | ||
| PCT/IB2015/059824 WO2016103146A1 (en) | 2014-12-22 | 2015-12-21 | Selective reduction of cysteine residues in il-17 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020113344A Division RU2765307C2 (ru) | 2014-12-22 | 2015-12-21 | Селективное восстановление цистеиновых остатков в антителах против il-17 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017126025A RU2017126025A (ru) | 2019-01-24 |
| RU2017126025A3 true RU2017126025A3 (ru) | 2019-11-12 |
| RU2719563C2 RU2719563C2 (ru) | 2020-04-21 |
Family
ID=55135470
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020113344A RU2765307C2 (ru) | 2014-12-22 | 2015-12-21 | Селективное восстановление цистеиновых остатков в антителах против il-17 |
| RU2017126025A RU2719563C2 (ru) | 2014-12-22 | 2015-12-21 | Селективное восстановление цистеиновых остатков в антителах против il-17 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020113344A RU2765307C2 (ru) | 2014-12-22 | 2015-12-21 | Селективное восстановление цистеиновых остатков в антителах против il-17 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11292833B2 (ru) |
| EP (1) | EP3237445A1 (ru) |
| JP (3) | JP7021950B2 (ru) |
| KR (2) | KR20230159617A (ru) |
| CN (4) | CN114249826B (ru) |
| AR (1) | AR103172A1 (ru) |
| AU (1) | AU2015370515B2 (ru) |
| BR (1) | BR112017010069A2 (ru) |
| CA (1) | CA2971541A1 (ru) |
| IL (2) | IL298761A (ru) |
| MX (1) | MX2017008410A (ru) |
| PH (1) | PH12017500967A1 (ru) |
| RU (2) | RU2765307C2 (ru) |
| SG (1) | SG11201703639QA (ru) |
| WO (1) | WO2016103146A1 (ru) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109890416A (zh) * | 2016-11-07 | 2019-06-14 | 西雅图基因公司 | 工程化半胱氨酸帽的分布 |
| AU2018309090B2 (en) * | 2017-08-04 | 2023-03-30 | Amgen Inc. | Method of conjugation of cys-mAbs |
| KR20210045425A (ko) * | 2018-08-15 | 2021-04-26 | 브리스톨-마이어스 스큅 컴퍼니 | 하류 크로마토그래피에서의 재산화에 의한 단백질 단편화 제어 전략 |
| CN109369806B (zh) * | 2019-01-14 | 2019-04-19 | 迈威(上海)生物科技有限公司 | 苏金单抗制品中半胱氨酸化变异体的去除方法 |
| EP4255927A1 (en) * | 2020-12-02 | 2023-10-11 | Fresenius Kabi Deutschland GmbH | Methods of selectively reducing antibodies |
| US20220251502A1 (en) * | 2020-12-22 | 2022-08-11 | Novartis Ag | Methods for reducing the oxidation level of cysteine residues in a secreted recombinantly-expressed protein during cell culture |
| CN113189184B (zh) * | 2021-04-28 | 2022-09-09 | 浙江大学 | 含有半胱氨酸的毛细管凝胶电泳样品缓冲液 |
| WO2023067626A1 (en) * | 2021-10-20 | 2023-04-27 | Dr. Reddy's Laboratories Limited | A cell culture process to produce an antibody composition |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4766205A (en) | 1985-11-13 | 1988-08-23 | Beatrice Companies, Inc. | Method for isolation of recombinant polypeptides in biologically active forms |
| JP2669859B2 (ja) * | 1987-08-04 | 1997-10-29 | 協和醗酵工業株式会社 | タンパク質の再活性化法 |
| JP3610395B2 (ja) * | 1991-08-26 | 2005-01-12 | 敏一 中村 | 成熟肝実質細胞増殖因子 |
| MXPA03007563A (es) * | 2001-02-23 | 2003-12-11 | Immunex Corp | Recuperacion incrementada de proteinas activas. |
| CA2468971A1 (en) * | 2001-12-04 | 2003-06-12 | Mitsubishi Pharma Corporation | Method of activating protein |
| JPWO2004056872A1 (ja) | 2002-12-20 | 2006-04-20 | 三菱ウェルファーマ株式会社 | タンパク質のチオール基を保護する方法 |
| GB0417487D0 (en) * | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| WO2006047340A2 (en) | 2004-10-22 | 2006-05-04 | Amgen Inc. | Methods for refolding of recombinant antibodies |
| JP5335422B2 (ja) * | 2005-06-17 | 2013-11-06 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 少なくとも１つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化 |
| GB0513852D0 (en) | 2005-07-06 | 2005-08-10 | Celltech R&D Ltd | Biological products |
| JP5068270B2 (ja) | 2006-01-31 | 2012-11-07 | ノバルティス アーゲー | 癌を処置するためのｉｌ−１７アンタゴニスト抗体 |
| DK1986612T3 (da) * | 2006-02-07 | 2012-10-29 | Shire Human Genetic Therapies | Stabiliserede proteinsammensætninger med en fri thioldel |
| DK3597659T3 (da) * | 2007-07-09 | 2023-04-03 | Genentech Inc | Forhindring af disulfidbindingsreduktion under rekombinant produktion af polypeptider |
| AU2009205995B2 (en) | 2008-01-18 | 2014-04-03 | Medimmune, Llc | Cysteine engineered antibodies for site-specific conjugation |
| PL2896404T3 (pl) * | 2009-06-04 | 2017-12-29 | Novartis Ag | Sposoby identyfikacji miejsc koniugacji IgG |
| GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
| EP4137514A1 (en) | 2010-10-08 | 2023-02-22 | Novartis AG | Methods of treating psoriasis using il-17 antagonists |
| AU2014259526B2 (en) * | 2010-11-05 | 2016-02-04 | Novartis Ag | Methods of treating ankylosing spondylitis using IL-17 antagonists |
| TW201307845A (zh) * | 2010-12-13 | 2013-02-16 | Novartis Ag | 預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法 |
| JP5782279B2 (ja) | 2011-01-20 | 2015-09-24 | 株式会社Ｓｃｒｅｅｎホールディングス | 基板処理方法および基板処理装置 |
| SI2771364T1 (sl) | 2011-10-27 | 2019-10-30 | Genmab As | Produkcija heterodimernih proteinov |
| JP2015504430A (ja) * | 2011-11-21 | 2015-02-12 | ノバルティス アーゲー | Ｉｌ−７アンタゴニスト及びｐｓａ応答又は非応答対立遺伝子を用いた乾癬性関節炎（ｐｓａ）を治療する方法 |
| AR103173A1 (es) * | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
-
2015
- 2015-12-18 AR ARP150104191A patent/AR103172A1/es unknown
- 2015-12-21 BR BR112017010069A patent/BR112017010069A2/pt not_active Application Discontinuation
- 2015-12-21 IL IL298761A patent/IL298761A/en unknown
- 2015-12-21 SG SG11201703639QA patent/SG11201703639QA/en unknown
- 2015-12-21 MX MX2017008410A patent/MX2017008410A/es unknown
- 2015-12-21 AU AU2015370515A patent/AU2015370515B2/en active Active
- 2015-12-21 KR KR1020237038206A patent/KR20230159617A/ko active Application Filing
- 2015-12-21 US US15/538,266 patent/US11292833B2/en active Active
- 2015-12-21 CN CN202210002418.0A patent/CN114249826B/zh active Active
- 2015-12-21 KR KR1020177016755A patent/KR102643328B1/ko active IP Right Grant
- 2015-12-21 EP EP15823803.0A patent/EP3237445A1/en active Pending
- 2015-12-21 RU RU2020113344A patent/RU2765307C2/ru active
- 2015-12-21 CA CA2971541A patent/CA2971541A1/en active Pending
- 2015-12-21 CN CN202111452382.8A patent/CN114010780B/zh active Active
- 2015-12-21 CN CN201580066406.2A patent/CN107001460B/zh active Active
- 2015-12-21 RU RU2017126025A patent/RU2719563C2/ru active
- 2015-12-21 CN CN202210002380.7A patent/CN114316044A/zh active Pending
- 2015-12-21 IL IL251893A patent/IL251893B2/en unknown
- 2015-12-21 JP JP2017551390A patent/JP7021950B2/ja active Active
- 2015-12-21 WO PCT/IB2015/059824 patent/WO2016103146A1/en active Application Filing
-
2017
- 2017-05-25 PH PH12017500967A patent/PH12017500967A1/en unknown
-
2022
- 2022-02-04 JP JP2022016666A patent/JP2022062194A/ja active Pending
- 2022-03-01 US US17/683,888 patent/US20220315650A1/en active Pending
-
2023
- 2023-06-01 JP JP2023091199A patent/JP2023110026A/ja active Pending